<- Go Home

Alimera Sciences, Inc.

Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals.

Market Cap

$301.3M

Volume

123.7K

Cash and Equivalents

$10.8M

EBITDA

$14.8M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$86.1M

Profit Margin

86.39%

52 Week High

$5.65

52 Week Low

$2.61

Dividend

N/A

Price / Book Value

7.48

Price / Earnings

-17.76

Price / Tangible Book Value

-5.50

Enterprise Value

$362.9M

Enterprise Value / EBITDA

23.91

Operating Income

$2.4M

Return on Equity

-34.57%

Return on Assets

0.98

Cash and Short Term Investments

$10.8M

Debt

$72.4M

Equity

$38.8M

Revenue

$99.7M

Unlevered FCF

$5.3M

Sector

Pharmaceuticals

Category

N/A

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches